The securities claims against Allakos concern Chief Operating Officer Adam Tomasi’s false and misleading statements on September 10, 2021 that the patient populations of Allakos’ Phase 2 and Phase 3 ENIGMA Trials had “identical” and “very similar” patient populations. When Allakos announced that the Phase 3 ENIGMA Trial failed on December 21, 2021, Allakos’ stock collapsed the next day, falling more than 90%. On February 15, 2022, Allakos hosted an investor day where it admitted that the Phase 3 ENIGMA Trial failed because of significant undisclosed differences between the patient populations of the Phase 2 and Phase 3 ENIGMA Trials, which was precisely contrary to Tomasi’s earlier statements.
If you purchased Allakos securities between September 10, 2021 and December 21, 2021 and have questions concerning your legal rights or your ability to participate in in the Class action please contact Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected].
Attorney Advertising. Prior results do not guarantee a similar outcome.
